UNSPSC 51181616: Diiodotyrosine

This classification denotes a thyroid hormone with the molecular formula C9H9I2NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6L57Q44ZWW, chemically known as 3,5-l-diiodotyrosine but generally known as diiodotyrosine, which bears US NIH Compound Identifier 6181. European Medicines Agency schedules Diiodotyrosine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13599MIG. World Health Organization schedules diiodotyrosine in its Anatomical Therapeutic Chemical (ATC) Classification.

As of Q4 2014, DIIODOTYROSINE remains the US FDA Preferred Term for this commodity. SMILES: IC1CC(CC(N)C(=O)O)CC(I)C1O.

UNSPSC 51181616 Diiodotyrosine is a Commodity code under which state and local governments procure generic multi-source pharmaceuticals and over-the-counter products for distribution across participating public health and administrative facilities. The work involves pharmaceutical manufacturers supplying products with specific National Drug Codes (NDCs), product information in designated formats (SKUs, UPCs, generic descriptions, strength, dosage form, trade names, packaging configurations, manufacturing locations), and pricing through authorized wholesale channels. Vendors must certify compliance with current Good Manufacturing Practices (cGMP), the Drug Supply Chain Security Act (DSCSA), and FDA requirements, maintain contractual relationships with at least two of three authorized wholesalers with chargeback systems in place, and demonstrate pricing flexibility through flat price, net price formats (NF30, NF60, NF90), or WAC-minus structures. Issuing bodies under this code include state purchasing offices administering cooperative purchasing alliances and the jurisdictions participating in those alliances.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted a Request for Proposal on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products for participating state and local facilities across Minnesota, Oregon, and other member jurisdictions. Evaluation criteria weight price competitiveness at 75 percent, fixed pricing for the contract term at 10 percent, compliance with administrative fee data format requirements at 5 percent, EDI capability at 5 percent, and agreement to a 3 percent administrative fee at 5 percent. All products must be available in the marketplace by May 15, 2026, with awarded contracts effective July 1, 2026 (new vendors) or aligned with existing expiration dates through June 30, 2028 (incumbents). Vendors must maintain commercial general liability insurance of $5 million per occurrence, network security and privacy liability of $2 million, and professional liability of $2 million. Submissions are made through the ePro procurement system using Excel spreadsheets converted to CSV format.